The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs

Author:

Kouspou Michelle M.,Fong Jenna E.,Brew Nadine,Hsiao Sarah T. F.ORCID,Davidson Seanna L.,Choyke Peter L.,Crispino Tony,Jain Suneil,Jenster Guido W.ORCID,Knudsen Beatrice S.,Millar Jeremy L.ORCID,Mittmann Nicole,Ryan Charles J.,Tombal Bertrand,Buzza MarkORCID

Abstract

AbstractProstate cancer is a heterogeneous cancer with widely varying levels of morbidity and mortality. Approaches to prostate cancer screening, diagnosis, surveillance, treatment and management differ around the world. To identify the highest priority research needs across the prostate cancer biomedical research domain, Movember conducted a landscape analysis with the aim of maximizing the effect of future research investment through global collaborative efforts and partnerships. A global Landscape Analysis Committee (LAC) was established to act as an independent group of experts across urology, medical oncology, radiation oncology, radiology, pathology, translational research, health economics and patient advocacy. Men with prostate cancer and thought leaders from a variety of disciplines provided a range of key insights through a range of interviews. Insights were prioritized against predetermined criteria to understand the areas of greatest unmet need. From these efforts, 17 research needs in prostate cancer were agreed on and prioritized, and 3 received the maximum prioritization score by the LAC: first, to establish more sensitive and specific tests to improve disease screening and diagnosis; second, to develop indicators to better stratify low-risk prostate cancer for determining which men should go on active surveillance; and third, to integrate companion diagnostics into randomized clinical trials to enable prediction of treatment response. On the basis of the findings from the landscape analysis, Movember will now have an increased focus on addressing the specific research needs that have been identified, with particular investment in research efforts that reduce disease progression and lead to improved therapies for advanced prostate cancer.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Reference116 articles.

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).

2. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424 (2018).

3. Tindall, D. J. & Scardino, P. T. Defeating prostate cancer: crucial directions for research — excerpt from the report of the Prostate Cancer Progress Review Group. Prostate 38, 166–171 (1999).

4. MBC alliance. Changing the landscape for people living with metastatic breast cancer. MBC alliance https://www.icrpartnership.org/library/file/7276/MBCA_Full_Report_Landscape_Analysis.pdf (2014).

5. BlueRibbonPanel. Cancer Moonshot Blue Ribbon Panel Report 2016. National Cancer Advisory Board https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/blue-ribbon-panel-report-2016.pdf (2016).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3